10-Q: Procyon Corporation Reports Modest Revenue Increase in Q3 2024, Operating Loss Widens

Procyon Corporation's Q3 2024 results show a slight revenue increase but a larger operating loss compared to the same period last year.

Summary

• Procyon Corporation's Q3 2024 net sales increased by approximately 7% to $1,198,539 compared to $1,124,824 in Q3 2023.
• For the nine months ended March 31, 2024, net sales increased by approximately 3% to $3,571,699 compared to $3,484,464 in the same period of 2023.
• The company reported an operating loss of $81,792 for Q3 2024, compared to an operating loss of $51,230 for Q3 2023.
• The operating loss for the nine months ended March 31, 2024, was $240,598, compared to $94,228 for the same period in 2023.
• The company's gross profit margin improved to approximately 78% for the nine months ended March 31, 2024, compared to approximately 76% for the same period in 2023.
• The company had cash of $325,130, inventories of $535,493, and net accounts receivable of $481,884 as of March 31, 2024.
• The company has $576,522 in Certificates of Deposit.
• The company had a valuation allowance of $229,066 as of March 31, 2024, and $0 as of June 30, 2023.
• The company had consolidated income tax net operating loss carryforwards for federal income tax purposes of approximately $904,000 as of March 31, 2024.

Sentiment

Score: 4

Explanation: The document presents mixed signals with increased revenue but also increased losses and a material weakness in internal controls. The sentiment is therefore cautiously negative.

Positives

• Net sales increased in both the quarter and nine-month periods ended March 31, 2024.
• Gross profit margin improved, indicating better profitability on sales.
• The company expanded its collagen line with the introduction of a individual size Collagen Gel tube and two new Wound Recovery Kit options for our professional market.

Negatives

• Operating expenses increased significantly, outpacing revenue growth.
• The operating loss widened in both the quarter and nine-month periods.
• A material weakness in internal controls over financial reporting was identified related to inadequate segregation of duties.

Risks

• Increased operating expenses could continue to pressure profitability.
• The material weakness in internal controls could lead to financial misstatements.
• The company's ability to recover deferred tax assets is dependent on future operating results.
• The company acknowledges risks related to business conditions in the skin and wound care market and the general economy, competitive factors, changes in product mix, production delays, product recalls, manufacturing capabilities, the loss of any significant customers or suppliers, general supply chain delays, the cost of rising inflation, cyber security breaches, natural disaster impacts, the impact of the COVID-19 pandemic on the Company's sales, operations and supply chain and other risks or uncertainties detailed in other of the Company's Securities and Exchange Commission filings.

Future Outlook

Management has expanded on the services and options the Company provides for its customers.

Management Comments

• Management of the Company, with the participation of the Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934 as of the end of the period covered by this report.
• Based on that evaluation, management, including the Chief Executive and Chief Financial Officer, has concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures were not effective in ensuring that all material information relating to the Company required to be disclosed in this report has been made known to management in a timely manner and ensuring that this information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and regulations, because of the identification of a material weakness in our internal controls over financial reporting, identified below, which we view as an integral part of our disclosure controls and procedures.

Industry Context

The company operates in the skin and wound care market, which is subject to competitive pressures, changing product mixes, and potential supply chain delays.

Comparison to Industry Standards

• It is difficult to compare Procyon Corporation's results to industry standards without knowing specific competitors and benchmarks.
• However, the company's gross profit margin of approximately 78% suggests a competitive position in its market.
• The increasing operating expenses and widening losses indicate potential challenges in managing costs compared to industry peers.

Related Party Transactions

• The line of credit is guaranteed by Justice W. Anderson, President and Chief Executive Officer.

Stakeholder Impact

• Shareholders may be concerned about the widening operating losses and the material weakness in internal controls.
• Employees may be affected by potential changes in staffing and internal control procedures.
• Customers and suppliers may be indirectly affected by the company's financial performance and operational efficiency.
• Creditors may be concerned about the company's ability to repay its debts given the increasing losses.

Next Steps

• The Company will continue to address changes needed to improve segregation of duties consistent with control objectives.
• The company expects that increased sales will enable it to add support staff, specifically in the accounting and shipping departments.
• A secondary effect of adding more staff will address needed improvements in segregation of duties consistent with control objectives.

Key Dates

Keywords

financial statements, operating loss, net sales, gross profit, Procyon Corporation, Q3 2024, 10-Q